Evidence map›Paper›PMID 34184271›Full record

ArticleCancer2021

Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration.

Temitope Rude, Dawn Walter, Shannon Ciprut, Matthew D Kelly, Chan Wang, Angela Fagerlin, Aisha T Langford, Herbert Lepor, Daniel J Becker, Huilin Li and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Review
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Prostate cancer statistics, 2025.CA: a cancer journal for clinicians
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Temitope RudeDepartment of Urology, New York University, New York, New York.
Dawn WalterDepartment of Urology, New York University, New York, New York.
Shannon CiprutDepartment of Urology, New York University, New York, New York.
Matthew D KellyDepartment of Urology, New York University, New York, New York.ORCID 0000-0001-6907-310X
Chan WangDepartment of Population Health, New York University, New York, New York.
Angela FagerlinSalt Lake City VA Informatics Decision-Enhancement and Analytic Sciences Center for Innovation, Salt Lake City, Utah.
Aisha T LangfordDepartment of Population Health, New York University, New York, New York.ORCID 0000-0003-1758-691X
Herbert LeporDepartment of Urology, New York University, New York, New York.
Daniel J BeckerPerlmutter Cancer Center, New York University, New York, New York.
Huilin LiPerlmutter Cancer Center, New York University, New York, New York.
Stacy LoebDepartment of Urology, New York University, New York, New York.ORCID 0000-0003-3933-9207
Joseph RavenellDepartment of Population Health, New York University, New York, New York.
John T LeppertDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Danil V MakarovDepartment of Urology, New York University, New York, New York.

Funding

John and Daria Barry Precision Oncology Center of Excellence at VANYHHSProstate Cancer FoundationThe Edward Blank and Sharon Cosloy-Blank Family FoundationU.S. Department of Veterans Affairs VA IIR 15-356
6 · The paper itself

Abstract

backgroundStudies have demonstrated that Black men may undergo definitive prostate cancer (CaP) treatment less often than men of other races, but it is unclear whether they are avoiding overtreatment of low-risk disease or experiencing a reduction in appropriate care. The authors' aim was to assess the role of race as it relates to treatment benefit in access to CaP treatment in a single-payer population.

methodsThe authors used the Veterans Health Administration (VHA) Corporate Data Warehouse to perform a retrospective cohort study of veterans diagnosed with low- or intermediate-risk CaP between 2011 and 2017.

resultsThe authors identified 35,427 men with incident low- or intermediate-risk CaP. When they controlled for covariates, Black men had 1.05 times the odds of receiving treatment in comparison with non-Black men (P < .001), and high-treatment-benefit men had 1.4 times the odds of receiving treatment in comparison with those in the low-treatment-benefit group (P < .001). The interaction of race and treatment benefit was significant, with Black men in the high-treatment-benefit category less likely to receive treatment than non-Black men in the same treatment category (odds ratio, 0.89; P < .001).

conclusionsAlthough race does appear to influence the receipt of definitive treatment in the VHA, this relationship varies in the context of the patient's treatment benefit, with Black men receiving less definitive treatment in high-benefit situations. The influence of patient race at high treatment benefit levels invites further investigation into the driving forces behind this persistent disparity in this consequential group.

Indexed as

Prostatic NeoplasmsVeteransBlack or African AmericanBlack PeopleHumansMaleRetrospective StudiesVeterans Healthdisparities researchprostate cancerracetreatmentVeterans Health Administration

Identifiers

PMID34184271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.